Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment–for health professionals (PDQ®)

SECTIONS

Changes to This Summary (12/08/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Localized Osteosarcoma and Malignant Fibrous Histiocytoma (MFH) of Bone

Added text about a series of three Children's Oncology Group pilot studies that used intensified chemotherapy with dexrazoxane cardioprotection for patients with newly diagnosed localized osteosarcoma (cited Schwartz et al. as reference 36 and level of evidence 2A).

Added Bielack et al. as reference 37 and level of evidence 1iiDi.

Recurrent Osteosarcoma and MFH of Bone

The Lung-Only Recurrence subsection was extensively revised.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Recurrent Osteosarcoma and MFH of Bone

Next section >
About This PDQ Summary